Overview Request Sample Pages Request Customization Download PDF
You are viewing: Rest Of Europe Biochips Market analysis
Part of: Biochips Market (Global)

The Rest Of Europe Biochips Market was valued at $721.7 Million in 2025 and projected to reach to $1100.8 Million by 2030, representing a compound annual growth rate of 8.8%. Rest Of Europe's biochips market demonstrates consistent growth momentum, driven by increasing healthcare expenditures and a strong emphasis on precision medicine adoption.

Rest Of Europe Biochips Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe Biochips Market Trends and Insights

  • This growth trajectory reflects Rest Of Europe's increasing adoption of advanced diagnostic and therapeutic biochip technologies across healthcare systems.
  • Rest Of Europe is benefiting from rising investments in precision medicine, growing prevalence of chronic diseases, and strengthening regulatory frameworks that support innovation in the biochips sector. The 8.8% compound annual growth rate (CAGR) observed in Rest Of Europe demonstrates the region's commitment to integrating biochip solutions into clinical practice and research environments.
  • Rest Of Europe's market expansion is driven by collaborations between academic institutions, healthcare providers, and biotechnology companies focused on developing next-generation biochip applications.
  • By 2030, Rest Of Europe is expected to solidify its position as a significant contributor to the European biochips ecosystem, supported by favorable reimbursement policies and increased healthcare spending on innovative diagnostic tools..

Key Market Statistics

  • CAGR (2025-2030) 8.8% CAGR
  • Market Size, 2025 ~USD 721.7 Million
  • Forecast, 2030 ~USD 1100.8 Million
  • Country Rest Of Europe

Rest Of Europe Biochips Market Overview

Market Valuation Growth :

Rest Of Europe's biochips market is projected to grow from $721.7 million in 2025 to $1,100.8 million by 2030, representing a robust 8.8% CAGR aligned with global expansion rates.

Precision Medicine Adoption :

Rest Of Europe is experiencing increased healthcare system investments in precision diagnostics and personalized therapeutic biochip solutions, driving market penetration across multiple countries.

Regional Healthcare Infrastructure :

Advanced healthcare systems across Rest Of Europe are integrating biochip technologies into clinical workflows, supported by regulatory frameworks and reimbursement policies favoring innovation.

Investment Momentum :

Rising venture capital and government funding for biotech initiatives in Rest Of Europe are accelerating biochip development, commercialization, and adoption across diagnostic and therapeutic applications.

Rest Of Europe Biochips Market Dynamics

  • The region's mature healthcare infrastructure and supportive regulatory environment create favorable conditions for biochip technology integration across diagnostic, monitoring, and therapeutic applications.
  • Healthcare providers are progressively investing in advanced diagnostic capabilities to improve patient outcomes and reduce treatment costs. Looking ahead to 2030, Rest Of Europe is expected to maintain steady market expansion as biochip technologies become more accessible and cost-effective.
  • Collaborative efforts between academic institutions, biotech companies, and healthcare systems will accelerate innovation and market penetration.
  • The region's commitment to digital health transformation and personalized medicine will further strengthen demand for biochip solutions across multiple therapeutic areas and clinical settings..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Rest Of Europe's biochips market is valued at $721.7 million in 2025 and is forecast to grow to $1,100.8 million by 2030, representing an 8.8% CAGR.
      • Rest Of Europe is experiencing increased adoption of biochip technologies driven by precision medicine initiatives and rising chronic disease prevalence.
      • Rest Of Europe's growth is supported by strong academic-industry partnerships and favorable regulatory environments for biochip innovation.
      • Rest Of Europe is expected to capture significant market share within the broader European biochips sector by 2030 through sustained healthcare investment.

      Biochips Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MICROFLUIDICS (Fabrication Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 8.8% from 2025 to 2030
      Largest Segment MICROARRAYS (Fabrication Technology)
      Market Size Base Year (Billions) ~USD 14.01 (2025)
      Revenue Forecast (Billions) ~USD 21.36 (2030)
      Segments Covered Products & Services, Type, Application, Fabrication Technology, End User, Product & Service

      Rest Of Europe Biochips Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Products & Services

      • Consumables
      • Instruments
      • Software & Services

      By Type

      • Cell Arrays
      • Dna Chips
      • Lab-On-A-Chip
      • Protein Chips
      • Tissue Arrays

      By Application

      • Agricultural Biotechnology
      • Cancer Diagnosis & Treatment
      • Clinical Diagnostic
      • Diagnostics
      • Drug Discovery
      • Expression Profiling
      • Gene Expression
      • Genomics
      • High-Throughput Screening
      • Ivd & Poc
      • Other Dna Chip Applications
      • Other Loac Applications
      • Other Protein Chip Applications
      • Proteomics
      • Snp Genotyping

      By Fabrication Technology

      • Microarrays
      • Microfluidics

      By End User

      • Academic & Research Institutes
      • Biotechnology & Pharmaceutical Companies
      • Contract Research Organizations
      • Hospitals & Diagnostic Centers
      • Other End Users

      By Product & Service

      • Consumables
      • Instruments
      • Software & Services

      Target Audience

      • Biochip Manufacturers & Developers : Need Rest Of Europe-specific market data to guide product development, regional expansion strategies, and competitive positioning within the growing European biochips ecosystem.
      • Healthcare Providers & Hospital Networks : Require insights into biochip technology adoption trends, clinical applications, and implementation best practices to enhance diagnostic capabilities and patient care delivery across Rest Of Europe.
      • Investment & Venture Capital Firms : Seek detailed market intelligence on Rest Of Europe's biochips sector to identify promising investment opportunities, assess market potential, and evaluate portfolio company growth prospects.
      • Pharmaceutical & Biotech Companies : Need regional market analysis to inform precision medicine strategies, companion diagnostic development, and therapeutic biochip commercialization plans in Rest Of Europe.
      • Healthcare Policy & Regulatory Bodies : Require market data and trend analysis to develop informed regulatory frameworks, reimbursement policies, and healthcare innovation strategies supporting biochip adoption in Rest Of Europe.

      Key Companies in the Rest Of Europe Biochips Market

      CompanyHQOwnershipStrongest segments
      ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyCustom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions,
      DECODE GENETICSIcelandPrivate CompanyInternal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects,
      JABILUnited StatesPublic CompanyRegulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem),
      AT&SCanadaPublic CompanyTurnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration,
      X-FABBelgiumPublic CompanyAutomotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes),
      GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other,
      10X GENOMICSUnited StatesPublic CompanyChromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents),
      CEPHEIDUnited StatesPrivate CompanyGeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics),
      BIOMéRIEUXFrancePublic CompanyClinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
      REVVITYUnited StatesPublic CompanyDiagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions,
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions,

      ATS AUTOMATION TOOLING SYSTEMS INC

      ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.

      DECODE GENETICS

      Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.

      JABIL

      Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.

      AT&S

      AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.

      X-FAB

      X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.

      GE HEALTHCARE

      GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.

      QIAGEN

      Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.

      ABBOTT

      Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.

      STANDARD BIOTOOLS

      Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.

      10X GENOMICS

      10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.

      CEPHEID

      Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.

      BIOMéRIEUX

      bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.

      REVVITY

      Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.

      Reasons to Buy this Report

      • Regional Market Sizing & Forecasts : Obtain precise market valuation data specific to Rest Of Europe, including 2025 baseline ($721.7M) and 2030 projections ($1,100.8M), enabling accurate business planning and investment decisions.
      • Growth Trajectory Analysis : Understand the 8.8% CAGR dynamics driving Rest Of Europe's biochips market expansion, identifying key growth drivers and market acceleration patterns unique to the region.
      • Competitive Landscape Intelligence : Gain insights into Rest Of Europe's competitive positioning, market consolidation trends, and emerging players reshaping the regional biochips ecosystem.
      • Healthcare System Integration Insights : Access detailed analysis of how Rest Of Europe's healthcare systems are adopting biochip technologies, including adoption rates, barriers, and implementation strategies.
      • Investment & Opportunity Assessment : Identify high-potential investment opportunities and market entry strategies tailored to Rest Of Europe's regulatory environment, reimbursement landscape, and healthcare priorities.

      Frequently asked questions

      What is the current market size of biochips in Rest Of Europe?

      Rest Of Europe's biochips market is estimated at $721.7 million in 2025.

      What is the projected market size for Rest Of Europe biochips by 2030?

      Rest Of Europe's biochips market is forecast to reach $1,100.8 million by 2030.

      What is the CAGR for Rest Of Europe's biochips market?

      Rest Of Europe's biochips market is expected to grow at a compound annual growth rate of 8.8% from 2025 to 2030.

      What factors are driving growth in Rest Of Europe's biochips market?

      Rest Of Europe's biochips market growth is driven by precision medicine adoption, increasing chronic disease prevalence, regulatory support, and academic-industry collaborations.

      How does Rest Of Europe's biochips market compare to other European regions?

      Rest Of Europe represents a significant segment of the European biochips market, with steady growth supported by regional healthcare investments and innovation ecosystems.

      RESEARCH METHODOLOGY

      This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.

      Secondary Research

      This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.

      Primary Research

      In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.

      A breakdown of the primary respondents is provided below:

      Biochips Market

      Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

      Note 2: Other designations include sales, marketing, and product managers.

      Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

      Biochips Market

      Data Triangulation

      After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

      Market Definition

      The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.

      Stakeholders

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Research Institutes
      • Academic Institutes
      • Contract Research Organizations
      • Research and Consulting Companies
      • Biochip Manufacturers and Distributors
      • DNA & Gene Chip Manufacturers and Distributors
      • Protein Microarray Manufacturers and Distributors
      • Lab-on-a-Chip Manufacturers and Distributors
      • Cell & Tissue Array Manufacturers and Distributors

      Report Objectives

      • To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
      • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

       

      Get the Full Biochips Market Report

      Full forecast, segment splits, and company analysis for all Biochips Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status